The lifetime prevalence of bipolar disorders and the use of antidepressant drugs in bipolar depression in Italy

Mauro Giovanni Carta, Eugenio Aguglia, Matteo Balestrieri, Joseph R. Calabrese, Filippo Caraci, Liliana Dell'Osso, Guido Di Sciascio, Filippo Drago, Carlo Faravelli, Maria Efisia Lecca, Maria Francesca Moro, Marcello Nardini, Gabriella Palumbo, Maria Carolina Hardoy

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: The prevalence of bipolar spectrum disorders in the community is under debate and the prescription of antidepressant drugs (ADs) in bipolar depression appears to be an underestimated problem. Objectives: To evaluate the prevalence of bipolar disorders by means of a screening instrument in seven communities within six regions of Italy and evaluate the appropriateness and number of prescriptions for ADs in bipolar depression. Methods: Study design: community survey. Study population: samples randomly drawn, after stratification from the adult population of municipal records. Sample size: 4999 people from seven communities within six regions of Italy. Tools: questionnaire on psychotropic drug consumption, prescription, health services utilization; Structured Clinical Interview NP for DSM-IV modified (ANTAS); Mood Disorder Questionnaire (MDQ). Training: interviewers were trained psychologists or medical doctors. Study limitations: the population studied did not represent a nationally representative multistage clustered area probability sample of households. Results: 3398 subjects were interviewed (68% of recruited sample). Positivity at MDQ (MDQ+) was higher in males (3.4% vs. 2.8%) but the difference was not significant (OR = 1.2, P = 0.37). The association between MDQ+ and Major Depressive Disorder (MDD) was statistically significant for both males (OR = 14.9, P <0.0001) and females (OR = 8.3, P <0.001); 30% of subjects with MDQ+ and MDD lifetime diagnosis were taking ADs. Conclusions: These overall rates of being MDQ+ are similar to community surveys conducted within USA and the use of ADs in people with MDQ+ and MDD diagnoses are.

Original languageEnglish
Pages (from-to)775-780
Number of pages6
JournalJournal of Affective Disorders
Volume136
Issue number3
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Bipolar Disorder
Italy
Antidepressive Agents
Mood Disorders
Major Depressive Disorder
Prescription Drugs
Surveys and Questionnaires
Interviews
Population
Drug Prescriptions
Sampling Studies
Psychotropic Drugs
Diagnostic and Statistical Manual of Mental Disorders
Sample Size
Health Services
Psychology

Keywords

  • Antidepressant drugs
  • Bipolar disorders
  • Community survey
  • Lifetime prevalence
  • Major depressive disorders
  • Mood Disorder Questionnaire

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

The lifetime prevalence of bipolar disorders and the use of antidepressant drugs in bipolar depression in Italy. / Carta, Mauro Giovanni; Aguglia, Eugenio; Balestrieri, Matteo; Calabrese, Joseph R.; Caraci, Filippo; Dell'Osso, Liliana; Di Sciascio, Guido; Drago, Filippo; Faravelli, Carlo; Lecca, Maria Efisia; Moro, Maria Francesca; Nardini, Marcello; Palumbo, Gabriella; Hardoy, Maria Carolina.

In: Journal of Affective Disorders, Vol. 136, No. 3, 02.2012, p. 775-780.

Research output: Contribution to journalArticle

Carta, MG, Aguglia, E, Balestrieri, M, Calabrese, JR, Caraci, F, Dell'Osso, L, Di Sciascio, G, Drago, F, Faravelli, C, Lecca, ME, Moro, MF, Nardini, M, Palumbo, G & Hardoy, MC 2012, 'The lifetime prevalence of bipolar disorders and the use of antidepressant drugs in bipolar depression in Italy', Journal of Affective Disorders, vol. 136, no. 3, pp. 775-780. https://doi.org/10.1016/j.jad.2011.09.041
Carta, Mauro Giovanni ; Aguglia, Eugenio ; Balestrieri, Matteo ; Calabrese, Joseph R. ; Caraci, Filippo ; Dell'Osso, Liliana ; Di Sciascio, Guido ; Drago, Filippo ; Faravelli, Carlo ; Lecca, Maria Efisia ; Moro, Maria Francesca ; Nardini, Marcello ; Palumbo, Gabriella ; Hardoy, Maria Carolina. / The lifetime prevalence of bipolar disorders and the use of antidepressant drugs in bipolar depression in Italy. In: Journal of Affective Disorders. 2012 ; Vol. 136, No. 3. pp. 775-780.
@article{faf432cdfa294ab79421fd803c98dcfa,
title = "The lifetime prevalence of bipolar disorders and the use of antidepressant drugs in bipolar depression in Italy",
abstract = "Background: The prevalence of bipolar spectrum disorders in the community is under debate and the prescription of antidepressant drugs (ADs) in bipolar depression appears to be an underestimated problem. Objectives: To evaluate the prevalence of bipolar disorders by means of a screening instrument in seven communities within six regions of Italy and evaluate the appropriateness and number of prescriptions for ADs in bipolar depression. Methods: Study design: community survey. Study population: samples randomly drawn, after stratification from the adult population of municipal records. Sample size: 4999 people from seven communities within six regions of Italy. Tools: questionnaire on psychotropic drug consumption, prescription, health services utilization; Structured Clinical Interview NP for DSM-IV modified (ANTAS); Mood Disorder Questionnaire (MDQ). Training: interviewers were trained psychologists or medical doctors. Study limitations: the population studied did not represent a nationally representative multistage clustered area probability sample of households. Results: 3398 subjects were interviewed (68{\%} of recruited sample). Positivity at MDQ (MDQ+) was higher in males (3.4{\%} vs. 2.8{\%}) but the difference was not significant (OR = 1.2, P = 0.37). The association between MDQ+ and Major Depressive Disorder (MDD) was statistically significant for both males (OR = 14.9, P <0.0001) and females (OR = 8.3, P <0.001); 30{\%} of subjects with MDQ+ and MDD lifetime diagnosis were taking ADs. Conclusions: These overall rates of being MDQ+ are similar to community surveys conducted within USA and the use of ADs in people with MDQ+ and MDD diagnoses are.",
keywords = "Antidepressant drugs, Bipolar disorders, Community survey, Lifetime prevalence, Major depressive disorders, Mood Disorder Questionnaire",
author = "Carta, {Mauro Giovanni} and Eugenio Aguglia and Matteo Balestrieri and Calabrese, {Joseph R.} and Filippo Caraci and Liliana Dell'Osso and {Di Sciascio}, Guido and Filippo Drago and Carlo Faravelli and Lecca, {Maria Efisia} and Moro, {Maria Francesca} and Marcello Nardini and Gabriella Palumbo and Hardoy, {Maria Carolina}",
year = "2012",
month = "2",
doi = "10.1016/j.jad.2011.09.041",
language = "English",
volume = "136",
pages = "775--780",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - The lifetime prevalence of bipolar disorders and the use of antidepressant drugs in bipolar depression in Italy

AU - Carta, Mauro Giovanni

AU - Aguglia, Eugenio

AU - Balestrieri, Matteo

AU - Calabrese, Joseph R.

AU - Caraci, Filippo

AU - Dell'Osso, Liliana

AU - Di Sciascio, Guido

AU - Drago, Filippo

AU - Faravelli, Carlo

AU - Lecca, Maria Efisia

AU - Moro, Maria Francesca

AU - Nardini, Marcello

AU - Palumbo, Gabriella

AU - Hardoy, Maria Carolina

PY - 2012/2

Y1 - 2012/2

N2 - Background: The prevalence of bipolar spectrum disorders in the community is under debate and the prescription of antidepressant drugs (ADs) in bipolar depression appears to be an underestimated problem. Objectives: To evaluate the prevalence of bipolar disorders by means of a screening instrument in seven communities within six regions of Italy and evaluate the appropriateness and number of prescriptions for ADs in bipolar depression. Methods: Study design: community survey. Study population: samples randomly drawn, after stratification from the adult population of municipal records. Sample size: 4999 people from seven communities within six regions of Italy. Tools: questionnaire on psychotropic drug consumption, prescription, health services utilization; Structured Clinical Interview NP for DSM-IV modified (ANTAS); Mood Disorder Questionnaire (MDQ). Training: interviewers were trained psychologists or medical doctors. Study limitations: the population studied did not represent a nationally representative multistage clustered area probability sample of households. Results: 3398 subjects were interviewed (68% of recruited sample). Positivity at MDQ (MDQ+) was higher in males (3.4% vs. 2.8%) but the difference was not significant (OR = 1.2, P = 0.37). The association between MDQ+ and Major Depressive Disorder (MDD) was statistically significant for both males (OR = 14.9, P <0.0001) and females (OR = 8.3, P <0.001); 30% of subjects with MDQ+ and MDD lifetime diagnosis were taking ADs. Conclusions: These overall rates of being MDQ+ are similar to community surveys conducted within USA and the use of ADs in people with MDQ+ and MDD diagnoses are.

AB - Background: The prevalence of bipolar spectrum disorders in the community is under debate and the prescription of antidepressant drugs (ADs) in bipolar depression appears to be an underestimated problem. Objectives: To evaluate the prevalence of bipolar disorders by means of a screening instrument in seven communities within six regions of Italy and evaluate the appropriateness and number of prescriptions for ADs in bipolar depression. Methods: Study design: community survey. Study population: samples randomly drawn, after stratification from the adult population of municipal records. Sample size: 4999 people from seven communities within six regions of Italy. Tools: questionnaire on psychotropic drug consumption, prescription, health services utilization; Structured Clinical Interview NP for DSM-IV modified (ANTAS); Mood Disorder Questionnaire (MDQ). Training: interviewers were trained psychologists or medical doctors. Study limitations: the population studied did not represent a nationally representative multistage clustered area probability sample of households. Results: 3398 subjects were interviewed (68% of recruited sample). Positivity at MDQ (MDQ+) was higher in males (3.4% vs. 2.8%) but the difference was not significant (OR = 1.2, P = 0.37). The association between MDQ+ and Major Depressive Disorder (MDD) was statistically significant for both males (OR = 14.9, P <0.0001) and females (OR = 8.3, P <0.001); 30% of subjects with MDQ+ and MDD lifetime diagnosis were taking ADs. Conclusions: These overall rates of being MDQ+ are similar to community surveys conducted within USA and the use of ADs in people with MDQ+ and MDD diagnoses are.

KW - Antidepressant drugs

KW - Bipolar disorders

KW - Community survey

KW - Lifetime prevalence

KW - Major depressive disorders

KW - Mood Disorder Questionnaire

UR - http://www.scopus.com/inward/record.url?scp=84857367787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857367787&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2011.09.041

DO - 10.1016/j.jad.2011.09.041

M3 - Article

VL - 136

SP - 775

EP - 780

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 3

ER -